iPSC-derived cell products

What these products are, and where they stand in the United States

An induced pluripotent stem cell is a somatic cell returned to a pluripotent state by introducing defined reprogramming factors, an approach first published for mouse cells in 2006^[S4] and for human cells in 2007.^[S5] Because the starting material is an ordinary somatic cell, these lines can be established from a patient or from a donor without the source constraints that apply to embryonic material. A therapeutic product is not the pluripotent cell itself but a differentiated cell derived from it, and the residual pluripotent cells that differentiation leaves behind are the central safety concern.

No iPSC-derived product is FDA-approved

The FDA maintains a list of licensed cellular and gene therapy products, and no product derived from induced pluripotent stem cells appears on it.^[S3] Everything described in this article is investigational in the United States. That is worth stating explicitly, because material written for other markets sometimes describes these applications in language that reads as though products were on the market. The route to market here is a Biologics License Application reviewed by the biologics centre.^[S6] Japan operates a conditional and time-limited approval pathway for regenerative medical products under its own legislation;^[S7] this article does not identify a US mechanism as equivalent to it, because no such equivalence was verified in preparing this page.

Applications in development

Retinal pigment epithelium

Retinal pigment epithelial cells are delivered to the eye either as a suspension or as a sheet. The eye is an unusually favourable site for a first application of this technology: the compartment is small and enclosed, the cell number is low, and the graft can be observed directly over time without removing it. That combination makes local retention easy to demonstrate and migration to other organs unlikely, which is a smaller nonclinical problem than most other targets present.

Cardiomyocytes

Cardiomyocytes present the opposite situation to the eye. The graft has to couple electrically with host tissue to contribute anything, and a cell population that beats but couples imperfectly can create a focus of abnormal electrical activity. Electrophysiological assessment is therefore not a general safety formality here but the specific question the application raises. Note also that these cells tend to remain immature relative to adult cardiomyocytes, so the maturity of the population is a product attribute that has to be defined and measured rather than assumed.

Dopaminergic neuron progenitors

Progenitor cells are delivered into the brain, where they are expected to survive, extend processes and function over years. The safety concern that dominates here is that the graft site is effectively irretrievable. A cell mass that grows abnormally in the eye can be observed and in principle addressed; one in the brain cannot be removed. That asymmetry is why tumorigenicity assessment for a central nervous system application is held to a stricter standard than the general framework alone would suggest, and why the observation period in animal studies is long.

The problems specific to this modality

Residual undifferentiated cells

A pluripotent cell that escapes differentiation retains the capacity to form tissue of multiple types, which is the property that made it useful and the property that makes it dangerous in a final product. Two related concerns follow. The detection problem is one of sensitivity: a small number of cells within a large population has to be found, and the assay's limit of detection is therefore a product specification rather than a laboratory detail. The second is that extended culture can allow genetic changes to accumulate, so the passage at which a product is manufactured is itself a safety-relevant parameter.

The FDA treats these products as belonging to two categories at once

The agency's guidance on preclinical assessment of cell and gene therapy products states that a product derived from an induced pluripotent stem cell has the possibility of expressing characteristics of both stem cell-derived and mature or functionally differentiated cell-derived products.^[S1] This is not a classification technicality. It means the nonclinical package has to address the concerns of both categories: the tumorigenicity and differentiation questions that attach to a stem cell source, and the function, purity and identity questions that attach to a differentiated cell product. A programme designed against only one of those frameworks will be incomplete, and the gap typically appears late, when the missing studies take longest to run.

Differentiation efficiency and batch consistency

Differentiation is never complete or uniform, so the product is a mixed population and its composition is what has to be specified. Three quantities need definition: the proportion of the intended cell type, the proportion of unintended lineages, and the maturity of the intended cells. Each requires an assay, and each assay needs a specification limit agreed before the material is made rather than derived from whatever the first batches happened to produce.

Persistence, migration and rejection

Three questions have to be answered separately. Whether the cells stay where they were placed, whether any reach other organs, and how long they survive. A donor-derived product adds a fourth: whether the recipient rejects it. That last one creates a methodological conflict, because the animal used to demonstrate survival must not reject human cells, which means it lacks the immune system that would reject them in a patient. The rejection question and the survival question therefore cannot be answered in the same animal.

The nonclinical work

Tumorigenicity assessment

Two lines of evidence are assembled. In vitro assays quantify residual undifferentiated cells and establish a limit of detection; the number reported means nothing without that limit stated alongside it. In vivo, the product is administered to severely immunodeficient animals and observed for tumour formation over a long period, because a slowly forming teratoma will not appear in a study designed around a conventional duration.

The tumorigenicity study must use the clinical product itself

The FDA guidance is direct on this point: studies conducted in animals to assess tumorigenicity should use the intended clinical product, not analogous animal cells.^[S2] The scheduling consequence is easy to underestimate. The study cannot begin until the manufacturing process is settled enough that the material being tested is the material that will be given to patients. A process change after the study starts may invalidate it. In practice this places the tumorigenicity study downstream of process lock, which makes process development, not the study itself, the item on the critical path for many programmes in this area.

Characterizing the cell population

Single-cell sequencing reports what cell types are present and in what proportion, which a bulk measurement of the same sample cannot do: a population that is uniformly half-mature and one that is half fully mature and half undifferentiated can give the same average. The practical use is to identify which markers distinguish the populations of concern, and then to build a simpler routine assay, typically flow cytometry, around those markers for batch release. Sequencing every batch is not the intent.

Biodistribution

Imaging follows the same animal over time and shows whether cells remain at the site; tissue-by-tissue quantification of a human-specific sequence measures how many cells are in each organ and is more sensitive. The two are complementary rather than alternatives. Which organs to sample should be decided in advance and should include those reached by the circulation from the administration site, not only those where cells are expected.

Allogeneic products and functional integration

For a donor-derived product the rejection question is addressed either in animals reconstituted with a human immune system or in a large animal receiving cells from another animal of the same species, and each arrangement answers a slightly different question from the clinical one. Where the product must integrate functionally, as cardiomyocytes must, electrophysiological methods measure whether it does. In that application the same measurement addresses safety, since imperfect integration is what creates an arrhythmic focus.

What to establish with the laboratory

Five things are worth establishing before award. What limit of detection the laboratory achieves for residual undifferentiated cells, and how that limit was established. Whether it can hold immunodeficient animals for the long observation periods tumorigenicity work requires, and what its historical background tumour rates are in those strains. Whether it understands that the study must use the clinical product rather than a surrogate, and how it would handle a mid-study process change.^[S2] What its biodistribution assay measures and its sensitivity per gram of tissue. And whether it has worked under the cell and gene therapy framework, given that these products are assessed against two product categories at once.^[S1]

About this article

This is an independent editorial article for people who commission nonclinical work in the United States. Regulatory positions are taken from FDA guidance and product listings as published. No product described here is FDA-approved, and this article makes no claim about the efficacy or safety of any investigational product. Where the source material described applications in terms that could read as marketed products, that framing has been corrected. It does not recommend any laboratory. Last reviewed: September 3, 2026.

References

1. FDA（CBER/OCTGT）— Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products（2013/11）. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preclinical-assessment-investigational-cellular-and-gene-therapy-products (accessed 2026-09-03)
2. FDA（CBER/OCTGT）— Preclinical Assessment of Investigational Cellular and Gene Therapy Products. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preclinical-assessment-investigational-cellular-and-gene-therapy-products (accessed 2026-09-03)
3. FDA（CBER/OTP）— Approved Cellular and Gene Therapy Products. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products (accessed 2026-09-03)
4. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006. https://europepmc.org/ (accessed 2026-09-03)
5. Takahashi K others. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007. https://europepmc.org/ (accessed 2026-09-03)
6. FDA（CBER）— Biologics License Applications (BLA) Process. https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-bla-process-cber (accessed 2026-09-03)
7. PMDA— Regenerative Medical Products. https://www.pmda.go.jp/english/ (accessed 2026-09-03)